Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Akebia Therapeutics, Inc.AKBA · Entity 6105 | SVP, Chief Development Officer | February 28, 2020 | March 03, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Akebia Therapeutics, Inc.
Report date February 28, 2020 · Filed March 03, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 88,133 |
Reported balance
After 2020-02-28 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2020-02-28 · Grant · Acquired 30,000 · Balance 88,133 F1: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date. F2: Includes 1,364 shares of the Issuer's common stock purchased on June 28, 2019 and 1,445 shares of the Issuer's common stock purchased on December 31, 2019, each under the Issuer's Amended and Restated 2014 Employee Stock Purchase Plan. |
| Common StockSEC Table I · non-derivative | Direct | 84,679 |
Reported balance
After 2020-02-28 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2020-02-28 · Sale · Disposed 3,454 · Balance 84,679 F3: This sale was made to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2019. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.87 · Expires 2030-02-28 | Direct | 85,000 |
Reported balance
After 2020-02-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-02-28 · Grant · Acquired 85,000 · Balance 85,000 F4: The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date.
F2: Includes 1,364 shares of the Issuer's common stock purchased on June 28, 2019 and 1,445 shares of the Issuer's common stock purchased on December 31, 2019, each under the Issuer's Amended and Restated 2014 Employee Stock Purchase Plan.
F3: This sale was made to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2019.
F4: The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 28, 2020 Filed Mar 3, 2020 00:26 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 85,000 | $0.00 Strike: $8.87 | $0.00 |
DisclosureSEC source: 0001562180-20-001934 · primarydocument.xml · derivative · entry 3 Tubridy Karen L · CIK 0001589888 · SVP, Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2030-02-28 F4 · derivative.exercise_date: The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 00:26 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 3,454 | $8.70 | $30,049.80 |
DisclosureSEC source: 0001562180-20-001934 · primarydocument.xml · nonDerivative · entry 2 Tubridy Karen L · CIK 0001589888 · SVP, Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,679 F3 · shares: This sale was made to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2019. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 00:26 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-001934 · primarydocument.xml · nonDerivative · entry 1 Tubridy Karen L · CIK 0001589888 · SVP, Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,133 F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date. F2 · balance_after: Includes 1,364 shares of the Issuer's common stock purchased on June 28, 2019 and 1,445 shares of the Issuer's common stock purchased on December 31, 2019, each under the Issuer's Amended and Restated 2014 Employee Stock Purchase Plan. Read SEC document |
| April 11, 2019 Filed Apr 12, 2019 20:00 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | Disposition to issuerCommon Stock | 6,075 | $7.70 | $46,777.50 |
DisclosureSEC source: 0000899243-19-010588 · doc4.xml · nonDerivative · entry 1 Tubridy Karen L · CIK 0001589888 · SVP, Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,324 F1 · shares: The proceeds from the disposition of these shares are to be used by the reporting person to cover tax liabilities associated with previously vested restricted stock units. Read SEC document |
| February 28, 2019 Filed Mar 5, 2019 21:07 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantEmployee Stock Option (Right to buy) · Derivative | 45,000 | $0.00 Strike: $7.28 | $0.00 |
DisclosureSEC source: 0001562180-19-001680 · primarydocument.xml · derivative · entry 2 Tubridy Karen L · CIK 0001589888 · SVP, Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2029-02-28 F3 · derivative.exercise_date: The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter. Read SEC document |
| February 28, 2019 Filed Mar 5, 2019 21:07 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-19-001680 · primarydocument.xml · nonDerivative · entry 1 Tubridy Karen L · CIK 0001589888 · SVP, Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,399 F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date. F2 · balance_after: Includes 1,170 shares of the Issuer's common stock purchased under the Issuer's 2014 Employee Stock Purchase Plan on December 31, 2018. Read SEC document |
| December 12, 2018 Filed Dec 13, 2018 13:18 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | Tax withholdingCommon Stock | 11,928 | $8.94 | $106,636.32 |
DisclosureSEC source: 0000899243-18-030797 · doc4.xml · nonDerivative · entry 1 Tubridy Karen L · CIK 0001589888 · SVP, Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,229 F1 · balance_after: Includes 639 shares acquired under the Akebia Therapeutics, Inc. stock purchase plan on June 29, 2018. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 21:14 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantEmployee Stock Option (Right to buy) · Derivative | 25,000 | $0.00 Strike: $14.30 | $0.00 |
DisclosureSEC source: 0001562180-18-001382 · primarydocument.xml · derivative · entry 2 Tubridy Karen L · CIK 0001589888 · SVP, Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-02-28 F3 · derivative.exercise_date: The options were granted by the Issuer pursuant to its 2014 Incentive Plan. 25% of the shares underlying this option will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 21:14 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 17,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-001382 · primarydocument.xml · nonDerivative · entry 1 Tubridy Karen L · CIK 0001589888 · SVP, Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,518 F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan. One hundred percent of the restricted stock units will vest on the third anniversary of the grant date. F2 · balance_after: The total amount of beneficial securities owned includes 591 shares of stock purchased on June 30, 2017 at $8.92 per share and 427 shares of stock purchased on December 31, 2017 at $12.39 per share in connection with the Issuer's Employee Stock Purchase Plan. Read SEC document |
| February 21, 2017 Filed Feb 23, 2017 21:02 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 36,500 | $10.14 Strike: $0.00 | $370,110.00 |
DisclosureSEC source: 0001562180-17-000882 · primarydocument.xml · derivative · entry 2 Tubridy Karen L · CIK 0001589888 · SVP, Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,500 Underlying: Common Stock · 36,500 shares Expires 2027-02-21 F2 · derivative.exercise_date: 25% of the shares underlying this option will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter. Read SEC document |
| February 21, 2017 Filed Feb 23, 2017 21:02 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 23,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-17-000882 · primarydocument.xml · nonDerivative · entry 1 Tubridy Karen L · CIK 0001589888 · SVP, Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan. One hundred percent of the restricted stock units will vest on the third anniversary of the grant date. Read SEC document |
| November 30, 2016 Filed Dec 2, 2016 21:05 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 130,000 | $0.00 Strike: $8.61 | $0.00 |
DisclosureSEC source: 0001562180-16-003658 · primarydocument.xml · derivative · entry 1 Tubridy Karen L · CIK 0001589888 · SVP, Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires 2026-11-30 F1 · derivative.exercise_date: This option will vest as to 25% of the shares of common stock subject to the award on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.